Manufacturers report positive results for upadacitinib monotherapy in phase 3 study for atopic dermatitis
In the Measure Up 2 study, upadacitinib monotherapy showed clinical improvement vs placebo (60% and 73% receiving upadacitinib 15 mg and 30 mg achieved EASI 75 vs 13% for placebo, p<0.001).
Source:
Biospace Inc.